Biotech
Arcellx
Arcellx raises $125M Series C at $1.5B valuation
$125M
Total Raised
Series C
Latest Round
2014
Founded
200+
Employees
9000 Virginia Manor Road, Beltsville, MD 20705
1 min read
Quick Facts
Valuation
$1.5B
Latest Round Size
$125M
Latest Round Date
June 2024
Arcellx: Series C Funding Round
Arcellx has successfully raised $125M in Series C funding, reaching a valuation of $1.5B.
Company Overview
Cell therapy company
Funding Details
The Series C round was led by Betta Pharmaceuticals, with participation from Ally Bridge Group, Frazier Healthcare Partners, EcoR1 Capital.
Company Information
- Headquarters: 9000 Virginia Manor Road, Beltsville, MD 20705
- Founded: 2014
- Employees: 200+
- Category: Biotech
Investment
Arcellx plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Betta Pharmaceuticals: Verified investor in Series C
- Ally Bridge Group: Verified investor in Series C
- Frazier Healthcare Partners: Verified investor in Series C
- EcoR1 Capital: Verified investor in Series C
Key Investors
Betta Pharmaceuticals
Lead Investor
Verified investor in Series C
Ally Bridge Group
Investor
Verified investor in Series C
Frazier Healthcare Partners
Investor
Verified investor in Series C
EcoR1 Capital
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M